Omthera Pharmaceuticals (OMTH) - NASDAQ
OMTH is defunct.
  • May 28, 2013, 8:11 AM

    Omthera (OMTH) rockets 99% to $13.50 following news that AstraZeneca (AZN) has agreed to acquire the heart-drug company for up to $443M. The upfront payment of $323M is worth $12.70 a share, while a secondary contingent payment of $120M is worth $4.70. AstraZeneca is +2.4%.

    | May 28, 2013, 8:11 AM
  • May 28, 2013, 2:48 AM

    AstraZeneca (AZN) has agreed to acquire Omthera Pharmaceuticals (OMTH) for up to $443M as the U.K. company carries out its strategy of building up its cardiovascular drug business. The price includes an upfront payment of $323M, or $12.70 a share, which represents an 88% premium to Omthera's close on Friday. AstraZeneca will pay another $120M based on the success of Omthera's experimental drug Epanova for treating very high levels of triglycerides, a fat found in the blood. (PR)

    | May 28, 2013, 2:48 AM
Company Description
We are an emerging specialty pharmaceutical company focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular disease. Epanova, currently our sole product candidate, is a late-stage,... More
Sector: Healthcare
Industry: Drugs - Generic
Country: United States